These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28432583)

  • 21. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy of generalized anxiety disorder.
    Davidson JR
    J Clin Psychiatry; 2001; 62 Suppl 11():46-50; discussion 51-2. PubMed ID: 11414551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin.
    Both C; Kojda G; Lange-Asschenfeldt C
    Expert Rev Neurother; 2014 Jan; 14(1):29-38. PubMed ID: 24308277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of relapse in generalized anxiety disorder by escitalopram treatment.
    Allgulander C; Florea I; Huusom AK
    Int J Neuropsychopharmacol; 2006 Oct; 9(5):495-505. PubMed ID: 16316482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
    Allgulander C; Hartford J; Russell J; Ball S; Erickson J; Raskin J; Rynn M
    Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatr Res; 2015 May; 64():88-98. PubMed ID: 25851751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
    Sheehan DV
    J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.
    Kasper S; Brasser M; Schweizer E; Lyndon G; Prieto R
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):125-32. PubMed ID: 24290532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relapse in anxiety disorders].
    Muntingh ADT; Batelaan NM; van Balkom AJLM
    Ned Tijdschr Geneeskd; 2019 Feb; 163():. PubMed ID: 30816655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder.
    Boschen MJ
    Can J Psychiatry; 2011 Sep; 56(9):558-66. PubMed ID: 21959031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.
    Bandelow B; Wedekind D; Leon T
    Expert Rev Neurother; 2007 Jul; 7(7):769-81. PubMed ID: 17610384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
    Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
    Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
    Katzman MA; Vermani M; Jacobs L; Marcus M; Kong B; Lessard S; Galarraga W; Struzik L; Gendron A
    J Anxiety Disord; 2008 Dec; 22(8):1480-6. PubMed ID: 18455360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generalized Anxiety Disorder and Major Depressive Disorder in Pregnant and Postpartum Women: Maternal Quality of Life and Treatment Outcomes.
    Misri S; Swift E
    J Obstet Gynaecol Can; 2015 Sep; 37(9):798-803. PubMed ID: 26605449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of Pharmacotherapy Response in Generalized Anxiety Disorder: A Systematic Review.
    Ferreira-Garcia R; Mochcovitch M; Costa do Cabo M; Nardi AE; Christophe Freire R
    Harv Rev Psychiatry; 2017; 25(2):65-79. PubMed ID: 28272131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disorders.
    Rogers MP; Warshaw MG; Goisman RM; Goldenberg I; Rodriguez-Villa F; Mallya G; Freeman SA; Keller MB
    Depress Anxiety; 1999; 10(1):1-7. PubMed ID: 10499183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generalized anxiety disorder: between now and DSM-V.
    Allgulander C
    Psychiatr Clin North Am; 2009 Sep; 32(3):611-28. PubMed ID: 19716993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pregabalin for the treatment of generalized anxiety disorder.
    Wensel TM; Powe KW; Cates ME
    Ann Pharmacother; 2012 Mar; 46(3):424-9. PubMed ID: 22395254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
    Davidson JR; Wittchen HU; Llorca PM; Erickson J; Detke M; Ball SG; Russell JM
    Eur Neuropsychopharmacol; 2008 Sep; 18(9):673-81. PubMed ID: 18559291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.